应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
VRDN Viridian Therapeutics, Inc.
未开盘 11-07 16:00:00 EST
24.71
+0.44
+1.81%
盘后
24.71
+0.00
0.00%
16:58 EST
最高
25.02
最低
24.03
成交量
145.26万
今开
24.03
昨收
24.27
日振幅
4.08%
总市值
18.42亿
流通市值
16.48亿
总股本
7,456万
成交额
3,586万
换手率
2.18%
流通股本
6,669万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Viridian Therapeutics, Inc.盘中异动 下午盘快速跳水5.06%
市场透视 · 10-01
Viridian Therapeutics, Inc.盘中异动 下午盘快速跳水5.06%
美国研究综述-Cintas、纳斯达克、Talen Energy
路透中文 · 09-24
美国研究综述-Cintas、纳斯达克、Talen Energy
Viridian Therapeutics, Inc.盘中异动 早盘股价大涨5.08%报22.13美元
市场透视 · 09-19
Viridian Therapeutics, Inc.盘中异动 早盘股价大涨5.08%报22.13美元
异动解读 | 加拿大皇家银行力挺Viridian Therapeutics,看好其创新药物潜力
异动解读 · 09-15
异动解读 | 加拿大皇家银行力挺Viridian Therapeutics,看好其创新药物潜力
异动解读 | 加拿大皇家银行上调Viridian Therapeutics目标价 股价盘中大涨5.53%
异动解读 · 09-13
异动解读 | 加拿大皇家银行上调Viridian Therapeutics目标价 股价盘中大涨5.53%
美国研究综述-星座能源公司、礼来公司、塔伦能源公司
Reuters · 09-13
美国研究综述-星座能源公司、礼来公司、塔伦能源公司
BUZZ--美国股票走势-金矿矿工、银矿矿工、华纳兄弟发现公司
Reuters · 09-13
BUZZ--美国股票走势-金矿矿工、银矿矿工、华纳兄弟发现公司
异动解读 | VRDN股价大涨5.51% 2.25亿美元融资推动旗舰药物进展
异动解读 · 09-12
异动解读 | VRDN股价大涨5.51% 2.25亿美元融资推动旗舰药物进展
BUZZ--美国股票走势-Fulcrum Therapeutics、Summit Therapeutics、Signet Jewelers
Reuters · 09-12
BUZZ--美国股票走势-Fulcrum Therapeutics、Summit Therapeutics、Signet Jewelers
BUZZ-Viridian Therapeutics 在增发 2.25 亿美元股票后上涨
Reuters · 09-12
BUZZ-Viridian Therapeutics 在增发 2.25 亿美元股票后上涨
异动解读 | 多家机构上调Viridian Therapeutics目标股价 公司股价大涨5%
异动解读 · 09-11
异动解读 | 多家机构上调Viridian Therapeutics目标股价 公司股价大涨5%
美国研究综述-埃克森美孚公司、Supernus 制药公司、威廉姆斯-索诺玛公司
Reuters · 09-11
美国研究综述-埃克森美孚公司、Supernus 制药公司、威廉姆斯-索诺玛公司
BUZZ--美国股票走势-Arrowhead Pharma、波音公司、Centessa Pharma
Reuters · 09-10
BUZZ--美国股票走势-Arrowhead Pharma、波音公司、Centessa Pharma
BUZZ--美国股票走势-惠普企业、富国银行、Rubrik
Reuters · 09-10
BUZZ--美国股票走势-惠普企业、富国银行、Rubrik
BUZZ-Viridian Therapeutics 公司眼疾治疗在后期研究中达到主要目标,业绩上升
Reuters · 09-10
BUZZ-Viridian Therapeutics 公司眼疾治疗在后期研究中达到主要目标,业绩上升
更新版 1-Viridian Therapeutics公司的眼部疾病疗法在后期研究中达到主要目标
Reuters · 09-10
更新版 1-Viridian Therapeutics公司的眼部疾病疗法在后期研究中达到主要目标
Viridian Therapeutics公司的眼病疗法在后期研究中达到主要目标
Reuters · 09-10
Viridian Therapeutics公司的眼病疗法在后期研究中达到主要目标
Viridian Therapeutics, Inc.盘中异动 大幅拉升5.01%
自选股智能写手 · 08-15
Viridian Therapeutics, Inc.盘中异动 大幅拉升5.01%
Viridian Therapeutics, Inc.盘中异动 下午盘股价大跌5.04%
自选股智能写手 · 08-14
Viridian Therapeutics, Inc.盘中异动 下午盘股价大跌5.04%
Viridian Therapeutics, Inc.盘中异动 股价大跌6.20%
自选股智能写手 · 08-08
Viridian Therapeutics, Inc.盘中异动 股价大跌6.20%
加载更多
公司概况
公司名称:
Viridian Therapeutics, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Viridian Therapeutics, Inc.于2014年6月17日在特拉华州成立,该公司是一家生物制药公司,专注于研究和开发针对严重和罕见疾病的潜在最佳药物。该公司瞄准的是竞争不激烈的疾病领域,在这些领域,已上市的疗法往往为提高疗效、安全性或给药便利性留出空间。该公司认为,第一代药物很少代表最佳解决方案,特别是在罕见病领域,而且有潜力开发差异化、同类最佳的药物,从而改善患者的治疗效果、减少副作用、提高生活质量、扩大市场准入和加强市场竞争。该公司正在开发三种候选产品:VRDN-001、VRDN-002和VRDN-003,这些产品正在开发中,用于静脉注射或皮下注射,以治疗患有甲状腺眼病(TED)的患者。该公司最先进的项目VRDN-001是一种靶向IGF-1R的差异化人源化单克隆抗体,用于治疗TED。
发行价格:
--
{"stockData":{"symbol":"VRDN","market":"US","secType":"STK","nameCN":"Viridian Therapeutics, Inc.","latestPrice":24.71,"timestamp":1731013200000,"preClose":24.27,"halted":0,"volume":1452559,"hourTrading":{"tag":"盘后","latestPrice":24.71,"preClose":24.71,"latestTime":"16:58 EST","volume":109212,"amount":2698628.54,"timestamp":1731016708295},"delay":0,"floatShares":66687500,"shares":74556520,"eps":-4.175521,"marketStatus":"未开盘","marketStatusCode":0,"change":0.44,"latestTime":"11-07 16:00:00 EST","open":24.03,"high":25.02,"low":24.03,"amount":35862313.399422,"amplitude":0.040791,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.175521,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1731056400000},"adr":0,"adjPreClose":24.27,"preHourTrading":{"tag":"盘前","latestPrice":24.02,"preClose":24.27,"latestTime":"09:29 EST","volume":100,"amount":2402,"timestamp":1730989799999},"postHourTrading":{"tag":"盘后","latestPrice":24.71,"preClose":24.71,"latestTime":"16:58 EST","volume":109212,"amount":2698628.54,"timestamp":1731016708295},"volumeRatio":1.846937,"impliedVol":0.2496,"impliedVolPercentile":0.0438},"requestUrl":"/m/hq/s/VRDN","defaultTab":"news","newsList":[{"id":"2472330740","title":"Viridian Therapeutics, Inc.盘中异动 下午盘快速跳水5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2472330740","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472330740?lang=zh_cn&edition=full","pubTime":"2024-10-01 02:23","pubTimestamp":1727720605,"startTime":"0","endTime":"0","summary":"北京时间2024年10月01日02时23分,Viridian Therapeutics, Inc.股票出现波动,股价急速下挫5.06%。Viridian Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.57%。其相关个股中,Nkgen Biotech Inc C/Wts 31/05/2028、Capricor Therapeutics, Inc.、Kezar Life Sciences, Inc.涨幅较大,Aditxt, Inc.、Seelos Therapeutics, Inc.、Gri Bio, Inc.较为活跃,换手率分别为216.30%、60.79%、58.52%,振幅较大的相关个股有Coeptis Therapeutics Holdings Inc C/Wts 31/12/2024 、Tc Biopharm Plc C/Wts 10/02/2028 、Surrozen Inc C/Wts 01/08/2031 ,振幅分别为87.30%、85.25%、48.53%。Viridian Therapeutics, Inc.公司简介:Viridian Therapeutics Inc 是一家临床阶段的生物制药公司,致力于开发多种候选产品,治疗甲状腺眼病患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410010223259719da5b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410010223259719da5b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VRDN","LENZ"],"gpt_icon":0},{"id":"2470008112","title":"美国研究综述-Cintas、纳斯达克、Talen Energy","url":"https://stock-news.laohu8.com/highlight/detail?id=2470008112","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470008112?lang=zh_cn&edition=full","pubTime":"2024-09-24 20:39","pubTimestamp":1727181557,"startTime":"0","endTime":"0","summary":"美国研究综述-Cintas、纳斯达克、Talen Energy路透9月26日 - 华尔街证券分析师周四修改了对几家美国上市公司的评级和目标价,其中包括 Cintas、Nasdaq 和 Talen Energy。股票条目按字母顺序排列。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240924:nL4T3L615A:11","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","DKNG","FNWB","CHK","TQQQ","FHB","CTAS","EHC","QLD","CME","01548","QID","TLNE","SQQQ","HTLF",".IXIC","LEGN","IE00BJJMRX11.SGD","TW","ICE","NBHC","KDP","KYMR","BANR","LU1093756325.SGD","EMR","VRDN","WABC","FINW","CPF","CBOE","PNTG","WOR","PROV","FLUT","GPN","LSEG.UK","ARTL","BMY","LPG","NDAQ","PSQ","TLN","ECL","MNQmain"],"gpt_icon":1},{"id":"2468650502","title":"Viridian Therapeutics, Inc.盘中异动 早盘股价大涨5.08%报22.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2468650502","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468650502?lang=zh_cn&edition=full","pubTime":"2024-09-19 22:37","pubTimestamp":1726756631,"startTime":"0","endTime":"0","summary":"北京时间2024年09月19日22时37分,Viridian Therapeutics, Inc.股票出现波动,股价大幅拉升5.08%。Viridian Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为1.20%。其相关个股中,Exicure, Inc.、Galmed Pharmaceuticals Ltd.、Edgewise Therapeutics, Inc.涨幅较大,Galmed Pharmaceuticals Ltd.、Exicure, Inc.、Portage Biotech Inc.较为活跃,换手率分别为3740.25%、648.97%、158.75%,振幅较大的相关个股有Exicure, Inc.、Galmed Pharmaceuticals Ltd.、Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025,振幅分别为81.66%、78.69%、52.97%。Viridian Therapeutics, Inc.公司简介:Viridian Therapeutics Inc 是一家临床阶段的生物制药公司,致力于开发多种候选产品,治疗甲状腺眼病患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240919223711a1db34ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240919223711a1db34ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VRDN","LENZ"],"gpt_icon":0},{"id":"1192775726","title":"异动解读 | 加拿大皇家银行力挺Viridian Therapeutics,看好其创新药物潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1192775726","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192775726?lang=zh_cn&edition=full","pubTime":"2024-09-15 21:34","pubTimestamp":1726407264,"startTime":"0","endTime":"0","summary":"9月13日,生物制药公司Viridian Therapeutics当日股价盘中大涨8.02%,引发市场关注。从相关报道来看,推动公司股价上涨的主要原因是加拿大皇家银行大幅上调了对Viridian的投资评级和目标价。加拿大皇家银行将Viridian的目标价从之前的35美元大幅上调至44美元,充分体现了该行对这家生物科技公司的看好预期。值得一提的是,加拿大皇家银行认为,Viridian不仅在创新药物研发方面拥有强大的科研实力,在资金实力方面同样出众,有利于推动公司持续发展和产品管线壮大。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VRDN"],"gpt_icon":0},{"id":"1151740453","title":"异动解读 | 加拿大皇家银行上调Viridian Therapeutics目标价 股价盘中大涨5.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=1151740453","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151740453?lang=zh_cn&edition=full","pubTime":"2024-09-13 21:32","pubTimestamp":1726234346,"startTime":"0","endTime":"0","summary":"据最新消息,加拿大皇家银行将生物制药公司Viridian Therapeutics, Inc.的目标价从35美元上调至44美元。这一利好消息出炉后,Viridian公司当日股价盘中大涨5.53%,报收于XX美元。此外,加拿大皇家银行高度评价了Viridian在创新药物研发方面的科研实力和资金实力,认为公司具备持续的发展潜力。目标价的大幅上调进一步提振了市场对Viridian的信心,投资者对公司长期前景的预期也趋于乐观。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VRDN"],"gpt_icon":0},{"id":"2467714846","title":"美国研究综述-星座能源公司、礼来公司、塔伦能源公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2467714846","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467714846?lang=zh_cn&edition=full","pubTime":"2024-09-13 15:51","pubTimestamp":1726213914,"startTime":"0","endTime":"0","summary":" 路透9月13日 - 周五,华尔街证券分析师修改了对几家美国上市公司的评级和目标价,其中包括星座能源公司、礼来公司和泰伦能源公司。* Fulcrum Therapeutics Inc :加拿大皇家银行将目标价从15美元下调至4美元 * Fulcrum Therapeutics Inc :加拿大皇家银行将其评级从 \"跑赢大盘 \"下调至 \"行业表现\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTD","FULC","LU2298322129.HKD","IE00BLSP4452.SGD","PEG","VRDN","BK4581","CEG","LU1165135440.EUR","BK4216","LU1267930813.SGD","ORKA","LU0417517546.SGD","KIDS","JNJ","BK4105","LU0234572021.USD","RH","USB","PLAY","SHLS","IE00BMG7P587.USD","LH","HAL","IE00BLSP4239.USD","ZBH","NRG","FERG","LU0130102774.USD","DOW","ALK","BK4592","TLN","MODV","GEV","VST","IE00BD4GTT62.SGD","LLY","EW","IBEX","AVTR","LU0965509101.SGD","KR","WDC","BK4212","LU1244550577.SGD","CPB"],"gpt_icon":1},{"id":"2467200010","title":"BUZZ--美国股票走势-金矿矿工、银矿矿工、华纳兄弟发现公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2467200010","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467200010?lang=zh_cn&edition=full","pubTime":"2024-09-13 00:02","pubTimestamp":1726156935,"startTime":"0","endTime":"0","summary":" * 个股走势的 Eikon 搜索字符串:[STXBZ] * The Day Ahead 新闻通讯: * The Morning News Call时事通讯: 9月12日 - 周四,华尔街股市变化不大,此前火热的生产者物价数据使得美联储小幅降息25个基点的可能性依然存在,而疫苗生产商莫德纳的股价则在不乐观的收入预期之后出现下滑。美东时间11:42,道琼斯工业平均指数 持平于40,842.63点。标普500指数 上涨0.11%,报5560.17点;纳斯达克综合指数 上涨0.34%,报17455.082点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTGR","ELF","RH","PSQ","DAL","DXD","VNOM","FULC","RYDE","OXM",".DJI","WMG","BK4585","MNQmain","WBD","BK4570",".IXIC","DOW","LOVE","SIG",".SPX","DOG","MPW","UDOW","AURA","CDE","LU1023059493.AUD","DDM","TQQQ","GEVO","QLD","DBI","SQQQ","CURV","MRNA","DJX","COIN","QID","HL","GEV","VRDN","GILD","KR","NEM","ONCT","NQmain","SDOW","USB","ALK","IPG"],"gpt_icon":1},{"id":"1119885590","title":"异动解读 | VRDN股价大涨5.51% 2.25亿美元融资推动旗舰药物进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1119885590","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119885590?lang=zh_cn&edition=full","pubTime":"2024-09-12 21:52","pubTimestamp":1726149142,"startTime":"0","endTime":"0","summary":"2024年9月12日,Viridian Therapeutics, Inc. 股价在盘中大涨5.51%,引发了市场的关注。此前周三晚间,VRDN公司完成发行约1070万股普通股和约130万股可转换优先股,融资总额高达2.25亿美元,超出了此前预期的1.5亿美元规模。公司表示,此次募集资金将主要用于推进临床开发项目,包括旗舰药物veligrotug。veligrotug是VRDN在研治疗甲状腺眼病的新药,在临床前期研究中显示出良好疗效,能够显著减轻甲状腺眼病症状。VRDN此次大规模融资有望为该新药的最终获批上市奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VRDN"],"gpt_icon":0},{"id":"2466427074","title":"BUZZ--美国股票走势-Fulcrum Therapeutics、Summit Therapeutics、Signet Jewelers","url":"https://stock-news.laohu8.com/highlight/detail?id=2466427074","media":"Reuters","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466427074?lang=zh_cn&edition=full","pubTime":"2024-09-12 21:19","pubTimestamp":1726147150,"startTime":"0","endTime":"0","summary":" * 个股走势的 Eikon 搜索字符串:[STXBZ] * The Day Ahead 新闻通讯: * The Morning News Call时事通讯: 9月12日 - 在美联储下周可能降息之前,华尔街期货周四在即将公布经济数据之前走高。美东时间9:08,道指电子盘 上涨0.10%,报40945点。标普500指数小型股 上涨0.12%,报收于5,568点;纳斯达克100指数小型股 上涨0.01%,报收于19,273.5点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237438978.USD","BK4207","LU1242518857.USD","LU1242518931.SGD","ALK","BK4532","BK4225","LU0566484027.USD","BK4534","BK4007","LU1559883803.SGD","LU0053671581.USD","BK4139","DOW","VRDN","BK4501","BK4203","BK4200","LU0979878070.USD","USB","BK4500","BK4539","BK4588","BK4548","BK4094","BK4533","BK4095","CURV","ELF","LENZ","BK4008","AURA","BK4568","BK4090","BK4559","LU2488822045.USD","BK4551","BK4585","SIG","BK4183","SMMT","IE00BFXG1179.USD","VNOM","BK4213","BK4504","LU0170899867.USD","MPW","FULC","LOVE"],"gpt_icon":1},{"id":"2466792042","title":"BUZZ-Viridian Therapeutics 在增发 2.25 亿美元股票后上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2466792042","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466792042?lang=zh_cn&edition=full","pubTime":"2024-09-12 20:08","pubTimestamp":1726142919,"startTime":"0","endTime":"0","summary":" 9月12日 - ** Viridian Therapeutics 股价上涨 1.1%,报 20.02 美元,此前该公司股价超出预期。** 该公司于周三晚些时候宣布定价 ,约1070万股,价格为18.75美元,优先股可转换为约130万股,总收益为2.25亿美元。** 交易规模从计划的 1.5 亿美元增加到 2.25 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN","LU2242652126.USD","IE0009355771.USD","LU2242646821.SGD","LU2112291526.USD","LU0868494617.USD","IE00BJT1NW94.SGD","LU0109394709.USD","LU0889565916.HKD","BK4139","LU1571399168.USD","BK4566","LU1023059063.AUD","BK4534","IE0002141913.USD","LU1983299246.USD","LENZ","IE00BFTCPJ56.SGD","LU1061106388.HKD","LU1057294990.SGD","IE00BJJMRZ35.SGD","BK4588","LU0289739699.SGD","BK4581","LU0058720904.USD","VRDN","BK4533","LU0320765992.SGD","LU0122379950.USD","BK4585","SG9999001440.SGD","IE00B4R5TH58.HKD","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"1125086147","title":"异动解读 | 多家机构上调Viridian Therapeutics目标股价 公司股价大涨5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1125086147","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125086147?lang=zh_cn&edition=full","pubTime":"2024-09-11 22:30","pubTimestamp":1726065029,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics, Inc.今日盘中大涨5.16%,股价上涨引起市场广泛关注。根据路透社的报道,多家机构对该公司进行了评级调整和目标股价上调,可能是导致该股价大涨的主要原因。据报道,研究机构B. Riley证券将Viridian Therapeutics的目标价从20美元上调至22美元,另一家研究机构BTIG将该公司的目标价从46美元大幅上调至56美元。目标价的上调显示分析师们看好该公司未来的发展前景和投资价值。Viridian Therapeutics是一家专注于开发治疗视力障碍疾病新药的生物制药公司。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 多家机构上调Viridian Therapeutics目标股价 公司股价大涨5%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VRDN"],"gpt_icon":0},{"id":"2466479575","title":"美国研究综述-埃克森美孚公司、Supernus 制药公司、威廉姆斯-索诺玛公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2466479575","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466479575?lang=zh_cn&edition=full","pubTime":"2024-09-11 15:59","pubTimestamp":1726041541,"startTime":"0","endTime":"0","summary":" 路透9月11日 - 华尔街证券分析师周三调整了对埃克森美孚、Supernus Pharmaceuticals和Williams-Sonoma 等几家美国上市公司的评级和目标价。要点 * Academy Sports and Outdoors Inc :TD Cowen将目标价从54美元上调至56美元 * 埃克森美孚 :Gerdes Energy Research将目标价从中性上调至买入 * 派克-汉尼汾公司 :TD Cowen 将目标价从 500 美元上调至 520 美元 * Supernus Pharmaceuticals Inc :Piper Sandler将其评级从 \"增持 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMA","LU1150488135.SGD","LU0323591593.USD","LU1169590202.USD","AXON","LU1244550221.USD","TGI","BK4023","LU1668664300.SGD","BK4588","PH","LU1150488218.USD","LU0306807586.USD","LU0149725797.USD","VRDN","FDS","BK4592","BK4144","IE00B775SV38.USD","JBI","LU0640476718.USD","LU2095319765.USD","BXP","LU2087621335.USD","XOM","CNC","ALLY","BBIO","LU1064131342.USD","CNOB","ZION","LU0320765489.SGD","LU2210149790.SGD","LU0889566641.SGD","ASO","LU1582986359.USD","WMB","WOOF","DV","BK4194","LU","SUPN","BK4585","WSM","CPB","CAC","BK4550","LU2210150020.SGD"],"gpt_icon":1},{"id":"2466468453","title":"BUZZ--美国股票走势-Arrowhead Pharma、波音公司、Centessa Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2466468453","media":"Reuters","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466468453?lang=zh_cn&edition=full","pubTime":"2024-09-10 23:59","pubTimestamp":1725983967,"startTime":"0","endTime":"0","summary":" * Eikon 个股走势搜索字符串:[STXBZ] * The Day Ahead 新闻通讯: * The Morning News Call时事通讯: 9月10日 - 标普500指数和纳斯达克指数周二上涨,多数大盘股上涨,目前市场焦点转向本周晚些时候的关键通胀数据,该数据可能进一步明确美联储9月18日降息的预期幅度。美东时间11:34,道琼斯工业平均指数 下跌0.5%,报40,639.63点。标普500指数 上涨0.17%,报5480.53点;纳斯达克综合指数 上涨0.41%,报16954.15点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COP","BKR","IONS","MCK","PSQ","XOM","SDOW","CRH","WYNN","HPE","DDM",".IXIC","MNQmain","LU","F","BA","AU","CVX","RBRK","DXD","RTX","GM","GE","COR","ASO","KGS","CAH","QID","DJX","VRDN","UDOW","SIRI","NQmain","PSX","CLF",".SPX","RLAY",".DJI","NEM","SQQQ","DOG","HES","FCX","ARWR","ALIM"],"gpt_icon":1},{"id":"2466453812","title":"BUZZ--美国股票走势-惠普企业、富国银行、Rubrik","url":"https://stock-news.laohu8.com/highlight/detail?id=2466453812","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466453812?lang=zh_cn&edition=full","pubTime":"2024-09-10 21:18","pubTimestamp":1725974312,"startTime":"0","endTime":"0","summary":" * Eikon 个股走势搜索字符串:[STXBZ] * The Day Ahead 新闻通讯: * The Morning News Call时事通讯: 9月10日 - 在本周晚些时候的关键通胀数据公布之前,华尔街周二将高开,这些数据可能会巩固对美联储预计在9月18日降息幅度的押注。美东时间9:07,道指电子盘 上涨0.11%,报40929点;标普500指数电子盘 上涨0.31%,报5496.5点;纳斯达克100指数电子盘 上涨0.36%,报18759点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0052756011.USD","LU0029864427.USD","IE00B19Z9Z06.USD","LU0198837287.USD","LU0208291251.USD","LU1064131342.USD","F","BK4561","ASO","FCX","LU0820562030.AUD","CRH","RTX","LU1880398471.USD","IE00BSNM7G36.USD","IE00B19Z9P08.USD","ORCL","KGS","LU0456854461.SGD","VRDN","LU2237438978.USD","LU0708994859.HKD","BK4206","CLF","IE0009356076.USD","LU0640476718.USD","WFC","GM","HPE","LU0162691827.USD","IE00BWXC8680.SGD","LU0965509010.AUD","RBRK","GE","NEM","LU0498741890.SGD","LU0320765489.SGD","BK4207","LU0354030438.USD","AU","BK4566","HPQ","LU0354030511.USD","LU0630314457.HKD","LU0496367417.USD","LU1883866441.USD","IONS","LU1992135399.USD","IE00BFSS7M15.SGD"],"gpt_icon":1},{"id":"2466431522","title":"BUZZ-Viridian Therapeutics 公司眼疾治疗在后期研究中达到主要目标,业绩上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2466431522","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466431522?lang=zh_cn&edition=full","pubTime":"2024-09-10 19:51","pubTimestamp":1725969086,"startTime":"0","endTime":"0","summary":" 9月10日 - ** 药物开发商Viridian Therapeutics 股价盘前上涨14%至16.19美元 ** 该公司称其试验性眼疾治疗达到了后期研究的主要目标 ** 该公司正在对甲状腺眼病患者进行名为 veligrotug 的治疗试验,甲状腺眼病是一种自身免疫性疾病,会导致炎症和眼周组织损伤。** VRDN说,veligrotug能明显减少 眼球的凸出。** VRDN称,在输注5次veligrotug后的 15周内,该疗法对所有 测量到的疾病症状都有 统计学意义上的 明显改善。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRDN","BK4139","LENZ"],"gpt_icon":0},{"id":"2466361474","title":"更新版 1-Viridian Therapeutics公司的眼部疾病疗法在后期研究中达到主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2466361474","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466361474?lang=zh_cn&edition=full","pubTime":"2024-09-10 19:24","pubTimestamp":1725967497,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) (第2段增加了股票走势,全文增加了细节) 路透9月10日 - Viridian Therapeutics 周二称,在一项晚期研究中,该公司用于治疗甲状腺眼病患者的实验性药物显著减少了眼球的凸出。该公司股价在盘前交易中震荡上涨了6.4%。甲状腺眼病是一种自身免疫性疾病,会导致眼周组织发炎和受损。该公司表示,veligrotug 药物的耐受性总体良好,没有出现与治疗相关的严重副作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRDN","LENZ"],"gpt_icon":0},{"id":"2466435976","title":"Viridian Therapeutics公司的眼病疗法在后期研究中达到主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2466435976","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466435976?lang=zh_cn&edition=full","pubTime":"2024-09-10 19:07","pubTimestamp":1725966429,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透9月10日 - Viridian Therapeutics 周二表示,其治疗甲状腺眼病患者的实验性药物在一项后期研究中达到了主要目标。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","VRDN"],"gpt_icon":0},{"id":"2459456474","title":"Viridian Therapeutics, Inc.盘中异动 大幅拉升5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459456474","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459456474?lang=zh_cn&edition=full","pubTime":"2024-08-15 23:18","pubTimestamp":1723735085,"startTime":"0","endTime":"0","summary":"北京时间2024年08月15日23时18分,Viridian Therapeutics, Inc.股票出现波动,股价急速拉升5.01%。Viridian Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为1.23%。其相关个股中,Cingulate Inc.、Tempest Therapeutics, Inc.、Geovax Labs Inc C/Wts 29/09/2025涨幅较大,Cingulate Inc.、Scisparc Ltd.、Altamira Therapeutics Ltd.较为活跃,换手率分别为6474.69%、2064.83%、574.59%,振幅较大的相关个股有Seastar Medical Holding Corp C/Wts 28/10/2027 、Tempest Therapeutics, Inc.、Cingulate Inc.,振幅分别为103.98%、79.83%、70.46%。Viridian Therapeutics, Inc.公司简介:Viridian Therapeutics Inc 是一家临床阶段的生物制药公司,致力于开发多种候选产品,治疗甲状腺眼病患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240815231805a1d474ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240815231805a1d474ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VRDN","BK4139","LENZ"],"gpt_icon":0},{"id":"2459367841","title":"Viridian Therapeutics, Inc.盘中异动 下午盘股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459367841","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459367841?lang=zh_cn&edition=full","pubTime":"2024-08-14 03:15","pubTimestamp":1723576515,"startTime":"0","endTime":"0","summary":"北京时间2024年08月14日03时15分,Viridian Therapeutics, Inc.股票出现异动,股价快速跳水5.04%。Viridian Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为1.59%。其相关个股中,Cardio Diagnostics Holdings Inc C/Wts To Pur Com、Psyence Biomedical Ltd C/Wts 25/01/2029、Orgenesis Inc.涨幅较大,Genprex, Inc.、冠科美博、Oragenics Inc.较为活跃,换手率分别为150.72%、140.05%、41.86%,振幅较大的相关个股有冠科美博、Zura Bio Limited C/Wts 、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 ,振幅分别为83.32%、59.26%、53.99%。Viridian Therapeutics, Inc.公司简介:Viridian Therapeutics Inc 是一家临床阶段的生物制药公司,致力于开发多种候选产品,治疗甲状腺眼病患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240814031515942004f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240814031515942004f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","VRDN"],"gpt_icon":0},{"id":"2457311192","title":"Viridian Therapeutics, Inc.盘中异动 股价大跌6.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457311192","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457311192?lang=zh_cn&edition=full","pubTime":"2024-08-08 21:33","pubTimestamp":1723123982,"startTime":"0","endTime":"0","summary":"北京时间2024年08月08日21时33分,Viridian Therapeutics, Inc.股票出现波动,股价快速下跌6.20%。Viridian Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为1.15%。其相关个股中,Conduit Pharmaceuticals Inc.、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Anew Medical, Inc.涨幅较大,Anew Medical, Inc.、Conduit Pharmaceuticals Inc.、Aditxt, Inc.较为活跃,换手率分别为183.08%、178.67%、40.39%,振幅较大的相关个股有Conduit Pharmaceuticals Inc.、Anew Medical, Inc.、Generation Bio Co.,振幅分别为27.33%、17.43%、14.41%。Viridian Therapeutics, Inc.公司简介:Viridian Therapeutics Inc 是一家临床阶段的生物制药公司,致力于开发多种候选产品,治疗甲状腺眼病患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808213302958900bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808213302958900bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","VRDN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.viridiantherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1456},{"period":"1month","weight":0.056},{"period":"3month","weight":0.6451},{"period":"6month","weight":0.7777},{"period":"1year","weight":0.755},{"period":"ytd","weight":0.1345}],"compareEarnings":[{"period":"1week","weight":0.0474},{"period":"1month","weight":0.0392},{"period":"3month","weight":0.1175},{"period":"6month","weight":0.1436},{"period":"1year","weight":0.3622},{"period":"ytd","weight":0.2531}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Viridian Therapeutics, Inc.于2014年6月17日在特拉华州成立,该公司是一家生物制药公司,专注于研究和开发针对严重和罕见疾病的潜在最佳药物。该公司瞄准的是竞争不激烈的疾病领域,在这些领域,已上市的疗法往往为提高疗效、安全性或给药便利性留出空间。该公司认为,第一代药物很少代表最佳解决方案,特别是在罕见病领域,而且有潜力开发差异化、同类最佳的药物,从而改善患者的治疗效果、减少副作用、提高生活质量、扩大市场准入和加强市场竞争。该公司正在开发三种候选产品:VRDN-001、VRDN-002和VRDN-003,这些产品正在开发中,用于静脉注射或皮下注射,以治疗患有甲状腺眼病(TED)的患者。该公司最先进的项目VRDN-001是一种靶向IGF-1R的差异化人源化单克隆抗体,用于治疗TED。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.315821},{"month":2,"riseRate":0.2,"avgChangeRate":-0.068987},{"month":3,"riseRate":0.3,"avgChangeRate":-0.074769},{"month":4,"riseRate":0.6,"avgChangeRate":0.030899},{"month":5,"riseRate":0.2,"avgChangeRate":-0.023661},{"month":6,"riseRate":0.5,"avgChangeRate":0.006153},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.012094},{"month":8,"riseRate":0.090909,"avgChangeRate":-0.09464},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.02948},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.053473},{"month":11,"riseRate":0.636364,"avgChangeRate":0.152821},{"month":12,"riseRate":0.4,"avgChangeRate":-0.070141}],"exchange":"NASDAQ","name":"Viridian Therapeutics, Inc.","nameEN":"Viridian Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viridian Therapeutics, Inc.(VRDN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Viridian Therapeutics, Inc.(VRDN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Viridian Therapeutics, Inc.,VRDN,Viridian Therapeutics, Inc.股票,Viridian Therapeutics, Inc.股票老虎,Viridian Therapeutics, Inc.股票老虎国际,Viridian Therapeutics, Inc.行情,Viridian Therapeutics, Inc.股票行情,Viridian Therapeutics, Inc.股价,Viridian Therapeutics, Inc.股市,Viridian Therapeutics, Inc.股票价格,Viridian Therapeutics, Inc.股票交易,Viridian Therapeutics, Inc.股票购买,Viridian Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viridian Therapeutics, Inc.(VRDN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Viridian Therapeutics, Inc.(VRDN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}